Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
Neptune Medical is a venture capital-funded medical device start-up. The company develops, manufactures, and commercializes high-volume, high-clinical utility, single-use medical devices for gastroenterology. Their innovative devices are designed to improve patient outcomes and enhance the precision and safety of minimally invasive procedures. Neptune Medical is known for its proprietary technologies that aim to provide better control, flexibility, and ease of use for surgeons and medical professionals. Their products are often used in procedures across various medical fields, including gastroenterology and other endoscopic applications.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products. The company was founded in 2011 and is located at Wayne, PA, USA.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
WhiteSwell is a science-driven company dedicated to improving the treatment of acute decompensated heart failure (ADHF), which is a leading cause of hospitalization and emergency room visits. The WhiteSwell team investigated the therapeutic potential of the lymphatic system in order to address this significant clinical need. Its solution is unique in that it allows fluid removal from both the interstitial and intravascular compartments.
Fe3 Medical Inc. engages in commercialization of a drug delivery technology that enables the safe, non-toxic transport of approximately 10 milligrams of iron across the skin for those who suffer with iron-deficiency anemia.
Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.
PLEXUSS is a high-growth education technology company that is changing the world by leveraging its Global Student Network to connect millions of students everywhere with real opportunity. We connect thousands of qualified students with life-changing educational opportunities daily. PLEXUSS’ exclusive social technology, matching algorithms, big data analytics, and Microsoft Accelerator recognized machine learning help students globally connect with most compatible post-secondary educational opportunities, engaging content, and other students.
Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.
Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.
Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.
BodyMedia pioneered the development of wearable body monitors that collect physiological data for use in improving health, wellness and fitness. Founded in 1999, the company today provides a variety of around-the-clock on-body monitors utilizing proprietary technology that has been clinically validated for accuracy. Data captured by BodyMedia devices is used by consumers as well as health and wellness professionals to guide behavioral changes to control weight and promote an active lifestyle – two factors that are routinely cited as keys to combat and manage serious medical conditions. BodyMedia has amassed one of the largest databases of information about the human body, and the technology has been used in more than 100 clinical research studies covering health issues such as obesity, COPD, diabetes, cystic fibrosis, cancer, bariatrics, sleep and intensive care. BodyMedia is privately held and based in Pittsburgh, PA. For more information, visit www.bodymedia.com.
IntraPace® has developed a novel implantable system to treat obesity. It is built on the proven technology used in millions of cardiac pacemakers and defibrillators each year. The abiliti® system is designed to be implanted via standard laparoscopic instruments without making any changes to the anatomy of the digestive system or placing any limitations on what a person can eat or drink.
Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.
Sonoma Orthopedic Products designs, develops, and delivers proprietary orthopedic implants for physicians to address problematic fractures. The WaviBodyâ„¢ technology platform allows for quick, minimally invasive surgical solutions for active patients. Direct to Bone...Back To Life.
Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.
Nfocus Neuromedical
Series B in 2007
Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.
Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modified ÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.